Meeting Archive:
CROI 2018: Latest on the dapivirine vaginal ring


Meeting Description:

Join Zeda Rosenberg (IPM) and Jared Baeten (MTN) for a brief presentation and discussion on the latest data on the dapivirine vaginal ring for HIV prevention. Initial data from the HOPE and DREAM open-label extension ring trials were presented at CROI 2018 and showed that the use of the ring cut HIV risk by 50 percent. Learn more about what these initial data show us, what additional data are expected and plans for the ring in the coming year. And, as always, what can advocates do to advance the agenda?

Details
Date: Thu, Mar 29, 2018
Time: 09:00 AM EDT
Duration: 1 hour
Host(s): AVAC
 Presenter Information
Zeda Rosenberg, ScD, International Partnership for Microbicides (IPM)
 
Dr. Zeda Rosenberg is the founder and chief executive officer of the International Partnership for Microbicides (IPM), a nonprofit product development partnership established in 2002 dedicated to developing new HIV prevention, and sexual and reproductive health products for women.
 
A microbiologist, epidemiologist, and widely recognized expert in HIV prevention, Dr. Rosenberg has been on the forefront of research on biological and behavioral factors for reducing HIV transmission for the past 30 years. Under Dr. Rosenberg’s vision, leadership and strategic direction, IPM developed the monthly dapivirine ring — the first long-acting product and first microbicide clinically shown to reduce women's HIV risk — in just 10 years, and secured support from donors and partners worldwide to develop a robust pipeline of promising HIV prevention products for women.
 
 

Jared Baeten, MD, PhD, Microbicide Trials Network (MTN)
 
Jared M. Baeten, M.D., Ph.D., is vice chair and professor in the Department of Global Health at the University of Washington, where he is also professor in the departments of Medicine and Epidemiology. His research focuses on the prevention of HIV and other sexually transmitted diseases, which he pursues through clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV transmission, and behavioral, translational, and implementation science research aimed at optimizing prevention delivery. In December 2016 he was named co-principal investigator of the U.S. National Institutes of Health-funded Microbicide Trials Network (MTN). Dr. Baeten was protocol chair of ASPIRE (MTN-020), a multinational phase III trial of the dapivirine vaginal ring for HIV prevention in women conducted through the MTN.